{"id":"NCT02677896","sponsor":"Astellas Pharma Global Development, Inc.","briefTitle":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","officialTitle":"A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-09","primaryCompletion":"2018-10-14","completion":"2024-07-31","firstPosted":"2016-02-09","resultsPosted":"2020-01-21","lastUpdate":"2025-07-17"},"enrollment":1150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Hormone Sensitive Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Enzalutamide","otherNames":["Xtandi"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Enzalutamide + Androgen Deprivation Therapy (ADT)","type":"EXPERIMENTAL"},{"label":"Placebo + Androgen Deprivation Therapy (ADT)","type":"PLACEBO_COMPARATOR"},{"label":"Placebo followed by Enzalutamide","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the efficacy of enzalutamide plus androgen deprivation therapy (ADT) as measured by radiographic progression-free survival (rPFS) based on central review. The study also evaluated the safety of enzalutamide plus ADT in mHSPC.","primaryOutcome":{"measure":"Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria","timeFrame":"From the date of randomization to the first objective evidence of rPD at any time or death (maximum duration was 26.6 months)","effectByArm":[{"arm":"Enzalutamide + Androgen Deprivation Therapy (ADT)","deltaMin":null,"sd":null},{"arm":"Placebo + Androgen Deprivation Therapy (ADT)","deltaMin":19.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":203,"countries":["United States","Argentina","Australia","Belgium","Canada","Chile","Denmark","Finland","France","Germany","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["31329516","40332939","39404227","37179240","35731340","35420921","32336645"],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=374"]},"adverseEventsSummary":{"seriousAny":{"events":244,"n":572},"commonTop":["Hot flush","Fatigue","Arthralgia","Back pain","Hypertension"]}}